506 related articles for article (PubMed ID: 15057291)
21. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
22. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
23. The current status of thalidomide in the management of multiple myeloma.
Glasmacher A; von Lilienfeld-Toal M
Acta Haematol; 2005; 114 Suppl 1():3-7. PubMed ID: 16166765
[TBL] [Abstract][Full Text] [Related]
24. Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone.
Montagnese F; Portaro S; Musumeci O; Migliorato A; Moggio M; Fagiolari G; Rodolico C
Muscle Nerve; 2015 Jun; 51(6):934-5. PubMed ID: 25524603
[No Abstract] [Full Text] [Related]
25. Pomalidomide for patients with multiple myeloma.
Gras J
Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
[TBL] [Abstract][Full Text] [Related]
26. Thalidomide.
Waldman AR
Clin J Oncol Nurs; 2000; 4(2):99-100. PubMed ID: 11107384
[No Abstract] [Full Text] [Related]
27. Lenalidomide in multiple myeloma.
Sirohi B; Powles R
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1559-70. PubMed ID: 19895240
[TBL] [Abstract][Full Text] [Related]
28. [An old drug as a carcinostatic. The new career of thalidomide].
Holzgrabe U
Pharm Unserer Zeit; 2007; 36(6):446-9. PubMed ID: 17957689
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide in the treatment of plasma cell malignancies.
Rajkumar SV; Kyle RA
J Clin Oncol; 2001 Aug; 19(16):3593-5. PubMed ID: 11504740
[No Abstract] [Full Text] [Related]
30. Thalidomide--a revival story.
Raje N; Anderson K
N Engl J Med; 1999 Nov; 341(21):1606-9. PubMed ID: 10564693
[No Abstract] [Full Text] [Related]
31. Lenalidomide.
Weisel K; Kanz L
Recent Results Cancer Res; 2014; 201():347-57. PubMed ID: 24756803
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide in solid malignancies.
Eisen T
J Clin Oncol; 2002 Jun; 20(11):2607-9. PubMed ID: 12039920
[No Abstract] [Full Text] [Related]
33. [Thalidomide: the revival].
Grosbois B; Duguet C
Rev Med Interne; 2001 Jan; 22(1):5-7. PubMed ID: 11218298
[No Abstract] [Full Text] [Related]
34. [Pomalidomide for multiple myeloma].
Dougé A; Lemal R; Chaleteix C
Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
[TBL] [Abstract][Full Text] [Related]
35. The revitalization of thalidomide.
Thomas DA; Kantarjian HM
Ann Oncol; 2001 Jul; 12(7):885-6. PubMed ID: 11521791
[No Abstract] [Full Text] [Related]
36. Immunomodulatory drugs.
Crane E; List A
Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
38. Thalidomide: an antineoplastic agent.
Amato RJ
Curr Oncol Rep; 2002 Jan; 4(1):56-62. PubMed ID: 11734114
[TBL] [Abstract][Full Text] [Related]
39. [Pomalidomide for multiple myeloma].
Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
[TBL] [Abstract][Full Text] [Related]
40. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
